Effectiveness of ustekinumab dose escalation in Crohn’s disease patients with insufficient response to standard‐dose subcutaneous maintenance therapy
Uri Kopylov(Sheba Medical Center), David Drobne, Darragh Storan, Davide De Marco, Eran Zittan(Emek Medical Center), Nicola Imperatore(Centre National de la Recherche Scientifique), Nikolas Plevris, Waqqas Afif, Marieke Pierik(Maastricht University Medical Centre), Denis Franchimont(McGill University Health Centre), Glen Doherty(University College Dublin), Iria Bastón‐Rey, Fabiana Castiglione, Frank Hoentjen(Radboud University Nijmegen), Anneline Cremer, Marie Truyens(Ghent University Hospital), Shaji Sebastian(University of Hull), Yago González Lama, Claire Liefferinckx, Manuel Barreiro‐de Acosta(Instituto de Investigación Sanitaria de Santiago), Vince Biemans(Radboud University Nijmegen), Shomron Ben‐Horin(Tel Aviv University), Zuzana Zelinková(Erasmus MC), Bar‐Gil Shitrit Ariella, Željko Krznarić(University Hospital Centre Zagreb), Jurij Hanžel(University of Ljubljana), Charlie W. Lees(Western General Hospital), Richard Harris(Southampton City Council), Cyrielle Gilletta, Klaudia Farkas, Tamás Molnár, Sally Myers(University of Hull), Roni Weisshof, Triana Lobatón, Stephan R. Vavricka(Triemli Hospital), Viktor Domislović(University Hospital Centre Zagreb)
Cited by 80
Related Papers
Host–microbe interactions have shaped the genetic architecture of inflammatory bowel disease
|Nature|2012|4.8k
ESPEN guidelines on nutrition in cancer patients
|Clinical Nutrition|2016|3k
Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease
|Nature Genetics|2008|2.6k
Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci
|Nature Genetics|2010|2.6k